Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

ntrolled study of 446 patients at 44 international sites is designed to assess the TAXUS moderate-release paclitaxel-eluting coronary stent system in reducing restenosis in high-risk patients, including de novo lesions with overlapping stents, lesions 26 mm or greater in length and small vessels. Lesion size ranged from 18 - 40 mm in length and 2.5 - 3.75 mm in diameter. TAXUS VI is the first randomized, controlled clinical trial to demonstrate durability of drug-eluting stents in complex lesions at four years. Follow-up included 98 percent of the patients enrolled at four years.

The study's results demonstrate a continued significant reduction in target lesion revascularization (TLR, or retreatment rate) as compared to the bare-metal stent control group at four years. The four-year TLR rate was 12.9 percent for the TAXUS Stent group, as compared with 21.4 percent for the control group (P=0.0082 (only two TLR events were reported between three and four years for the TAXUS Stent group)). The rate of patients living free of TLR events was 87.1 percent at four years for the TAXUS Stent group, as compared to 78.6 percent for the bare-metal stent control group.

The four-year results for TAXUS VI support long-term safety with the increased levels of paclitaxel in the moderate-release formulation used in the study. Even with an in vitro dosing rate 8-10 times greater than the commercialized slow-release formulation, no compromise in safety was observed. The TAXUS Stent group continues to report no new stent thrombosis after two years with a low 2.4 percent cardiac death rate.

Boston Scientific launched the slow-release formulation TAXUS Express2 paclitaxel-eluting coronary stent system in Europe and other international markets in 2003 and in the United States in 2004. The Company launched the slow-release formulation TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system in Europe and other international markets in 2005. The TAXUS Express modera
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... 4, 2015  Allergan plc (NYSE: AGN ) a ... , CEO and President of Allergan, will provide an overview ... Global Healthcare Conference 2015 in New York, NY ... The presentation will take place on Thursday, September ... Hyatt New York, 109 East 42nd Street, New ...
(Date:9/4/2015)... Research and Markets ... the "Veterinary Pharmaceutical Submissions in the EU ... to their offering. This practical two-day ... constituent parts of the application for marketing authorisation ... marketing authorisation is sought in the European Union, ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... Expanding its offering of passive safety devices to protect ... Braun Medical Inc. (B. Braun) recently announced that the ... of the company,s Introcan Safety ® 3 Closed ... Safety ® IV Catheter. B. Braun made the ...
... is well known that ophthalmologists around the world often ... (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to ... efficacy. AMD Alliance International (AMDAI) is ... of a concerning surge in eye infections over the ...
Cached Medicine Technology:Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety® 3 Closed IV Catheter 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 3
(Date:9/4/2015)... , ... September 04, 2015 , ... ... CEREC technology is now available at CitiDent. CEREC is a newer method for ... to saving time for patients by eliminating the need for multiple appointments, CEREC ...
(Date:9/4/2015)... Pittsburgh, PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for ... Cups could be their solution. , The patent-pending K Med Cups provide a quick and ... they help to relieve a cold, flu or cough. As a result, they enhance comfort ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference ... in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & Spa has ... are doctors and researchers at the top of their field and will be ...
(Date:9/4/2015)... ... , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and ... 400 meters final, with an impressive 44.89 seconds at the 2015 North American, Central ... in August 2015. The 44.64 time is a new NACAC Championship record. , ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... details involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what ... with the Vatican and society is. Yisrayl also provides the meaning of his own name ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... , , , SILVER SPRING, ... Wellness Center has selected Artefill, the first and only FDA-approved microsphere-enhanced ... who are looking for a longer lasting dermal filler. Dr. Gonzalez ... to its proven success and effectiveness for the correction of wrinkles. ...
... , , WASHINGTON, Aug. 24 ... Veterans Affairs (VA) is taking steps to assist Veterans seeking compensation ... hidden wounds of war are being addressed vigorously and comprehensively by ... the 21st century," said Secretary Shinseki. , , ...
... , , , , ... the most powerful person in healthcare by readers of Modern ... whose name has become inextricably linked with healthcare reform, topped the ... , , "Think about healthcare reform. Now, try ...
... AUBURN HILLS, Mich., Aug. 24 ... leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable ... collaboration agreement with a major tobacco company for the ... (FSC) cigarettes. FSC cigarettes are designed to meet government ...
... , , , EMERYVILLE, Calif., ... , Inc. (NYSE-Amex: NBY ), a clinical stage ... a wide range of bacterial, viral, and fungal infections, announced today ... the 47th Annual Meeting of the Infectious Diseases Society of America ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
Cached Medicine News:Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Obama Named the Most Powerful Person in Healthcare 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 2Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5
... The Biomet Ankle ... ideally suited for,tibiotalocalcaneal ... second-generation nail affords ... fixation that incorporates ...
... clinical and economic issues of cerclage wiring, ... to maximize tension control while minimizing invasion ... efficient instrumentation with a simple technique. , ... indicated for general orthopaedic trauma surgery involving: ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... of DePuy's aggressive innovations have become the ... be equalled. The AML Total Hip ... efficiently address and effectively meet the needs ... With greater than 15 years of ...
Medicine Products: